Sema4 Launches New Genomic Testing and Digital Tools for Use in Oncology
30 Mai 2019 - 5:20PM
Business Wire
Demos will be available at the ASCO Annual
Meeting in Chicago
Sema4, a patient-centered health intelligence company, today
announced the launch of several new genomic testing services and
digital tools to help oncologists deliver on the promise of
precision medicine. Together, these products provide a
comprehensive approach that can be used throughout a patient’s
journey, from assessing risk to analyzing cancer and monitoring in
remission. Demonstrations of the products will be available at
Sema4’s booth (#7140) at the American Society for Clinical Oncology
2019 Annual Meeting taking place in Chicago from May 31 to June
4.
Sema4’s new genomic profiling solution that will soon be
available for oncology includes whole exome sequencing (for tumor
and normal samples) and whole transcriptome sequencing (for tumor
samples only). Based on 250x tumor coverage and 100x normal
coverage across all genes, with 100 million RNA reads, these
services provide clinically actionable information about a broad
range of genomic variants, gene fusion and alternative splicing,
and tumor mutational burden and microsatellite instability. The
services are designed for use with FFPE, bone marrow, blood, or
saliva samples.
The new digital tools are built on Sema4’s innovative
Centrellis™ health intelligence platform and are currently used for
research purposes. They include:
- Patient Journey — providing an
interactive timeline visualization of the patient’s health journey,
complete with diagnoses, treatments, molecular profiles, and
more
- Cohort Builder — offering the ability
to define groups of patients according to specific parameters such
as stage, histology, and treatments to understand treatment
patterns, identify appropriate clinical trials, and enable
data-driven decisions about patient care
- VONC — automated variant curation
platform pulling from a wide array of databases to support curation
of genetic information at scale with the most relevant clinical
evidence to inform therapy decisions
Clinicians at the Mount Sinai Health System, together with
Sema4, have been jointly developing and piloting these digital
tools for application in oncology.
“Sema4 is helping the objectives of the Tisch Cancer Institute
because it’s aggregating clinical data sets on our patients.
Marrying that with the genomic information and deploying it in
usable tools is allowing us to have better insights about what’s
happening in our patient population,” said Ramon Parsons, MD, PhD,
Director of the Tisch Cancer Institute and Chair of the Department
of Oncological Sciences at Icahn School of Medicine at Mount
Sinai.
William Oh, MD, Chief of the Division of Hematology and Medical
Oncology at Mount Sinai and Deputy Director of the Tisch Cancer
Institute at the Icahn School of Medicine at Mount Sinai commented:
“Working with a large healthcare system and as a practicing
oncologist myself, the most important thing is getting this
molecular data and the informatics in a timetable that allows me to
continue to take care of my patients. Working with a company like
Sema4 allows us to make the best decisions for our patients to get
the best possible outcomes.”
According to Andrew Kaufman, MD, Vice Chairman of the Department
of General Thoracic Surgery at Mount Sinai, “In healthcare, like
any other industry, we’re really looking for efficiency in
connecting the dots of so much data. Sema4 has come up with a novel
way to look at patient data that is extremely powerful. I use these
tools almost like a Google search, looking up information about my
patients’ clinical and scientific data to give each person the best
care.”
Elisa Port, MD, Chief of Breast Surgery and Director of the
Dubin Breast Center at Mount Sinai, commented: “Sema4 is going to
have a very widespread impact on the patients we treat here because
the company’s tests open up the opportunity for genetic testing
across a much broader base of patients and streamline and expedite
the process. Sema4 helps us by quickly getting us the genetic
testing information we need so we can make important clinical
decisions about surgery options for each individual.”
“Sema4’s mission to help physicians implement precision medicine
is built on our deep foundation in data science and developing
genomic tests,” said Eric Schadt, PhD, Founder and Chief Executive
Officer of Sema4. “Our team’s expertise in data mining, analysis,
machine learning, and predictive modeling gives us a unique
advantage in generating and making sense of information in ways
that will give oncologists an edge in battling cancer, particularly
when combined with advanced genomic profiling.”
About Sema4
Sema4 is a
patient-centered health intelligence company founded
on the idea that more information, deeper analysis, and increased
engagement will improve the diagnosis, treatment,
and prevention of disease. Sema4 is dedicated to transforming
healthcare by building dynamic models of human health and defining
optimal, individualized health trajectories, starting in the areas
of reproductive health and oncology. Centrellis™, our
innovative health intelligence platform, is enabling us to generate
a more complete understanding of disease and wellness and
to provide science-driven solutions to the most pressing
medical needs. Sema4 believes that patients should be treated as
partners, and that data should be shared for the benefit of
all.
For more information, please visit sema4.com and connect
with Sema4 on Twitter, LinkedIn,
Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190530005605/en/
Nicole Litchfield415.793.6468nicole@bioscribe.com